COMPASS Pathways (CMPS.Q) signed an MOU with South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London. https://youtu.be/DUqcroWEjLc…
Search Results for: CMPS.Q
COMPASS Pathways (CMPS.Q) signed an MOU with South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King’s College London. The…
COMPASS Pathways (CMPS.Q) reported further results from a Phase I study on their COMP360 psilocybin conducted at King’s College London. The study was a randomized, double-blind, placebo-controlled study intended…
A study was published today in the New England Journal of Medicine which tested COMPASS Pathways’ (CMPS.Q) COMP360 psilocybin. The study is a phase II double-blind, randomized, controlled trial…
“Life is too short to be small.” – Tim Ferriss, The 4-Hour Workweek Every psychedelics company starts its investor deck off with a fact about the quickly changing regulatory…
Cut the kumbaya shit Throwing the words profit and psychedelic drugs into a sentence would have lead to awkward and confused looks 5 years ago. But we have come…
Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
Psychedelics have showed tremendous potential in treating neurological conditions such as major depressive disorder, PTSD, ALS, and generalized anxiety. Investors jumped on the opportunity, sending market values skyrocketing. It’s…
Interest in the psychedelic market is as high as Matt Gaetz and Joel Greenberg on a night out, but the accompanying FOMO has the potential to muddy the market,…
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence of psychedelics’ healing properties,…